2026-10-15 Other Bull
Eli Lilly Breaks Downtrend as Funds Rotate into Healthcare Technical breakout plus defensive sector rotation draws inflows to LLY
D1 +3.5% · since +0.4%
2026-10-02 → 10-13 Product Bull
Retatrutide Set as Long-Term Growth Driver; FDA Submission Planned Early 2027 Media stress efficacy and timeline, potentially more important than Q3 earnings
D1 -0.6% · +5d +3.2%
› 2 waves of this story2026-10-02 TRIUMPH-2 shows 59.5% no longer obese; could reshape obesity drug market2026-10-13 Media stress efficacy and timeline, potentially more important than Q3 earnings2026-10-13 Company Bull
Eli Lilly Expects Up to $87B 2026 Revenue; Stock Still Looks Undervalued Multiple outlets highlight dominance in weight-loss market and explosive growth, suggesting premium valuation is justified
D1 -1.4% · since +7.8%
2026-10-12 Product
Eli Lilly Combo Shows Stronger Weight Loss but Higher Dropout Trial data shows combo beats Zepbound alone, yet discontinuation rates far higher
D1 +0.3% · since +6.3%
2026-10-12 Analyst Bull
Cowen Sees LLY Q3 Revenue Beat, Strong Mounjaro Growth Analyst estimates Q3 revenue $22.5B above consensus, Mounjaro up 56% YoY
D1 +0.3% · since +6.3%
2026-10-09 Capital
Lilly's Largest Shareholder Files to Sell $347M Stock Shareholder sale contrasts with analyst price target hikes, drawing attention
D1 +0.8% · +5d +6.6%
2026-10-07 Company Bull
Eli Lilly Expands Gate Bioscience Pact in $870M Protein Deal Expanded drug-discovery partnership; shares up ~3.6%
D1 +2.7% · +5d +1.7%
2026-10-07 Product Bull
GLP-1 Drugs May Slow Biological Aging, Benefiting LLY Studies show GLP-1s reduce biological age by 2-3 years, boosting LLY's metabolic franchise
D1 +2.7% · +5d +1.7%
2026-10-05 Product
Lilly to Present Dermatology Data at Fall Clinical 2026 21 presentations across dermatology, EBGLYSS data reinforce durable control
D1 +0.0% · +5d +3.5%
2026-10-02 → 10-05 Regulation Bull
Lilly's Jaypirca Gets FDA Approval for First-Line CLL/SLL FDA expands Jaypirca label to first-line setting, bolstering Lilly's oncology portfolio
D1 -0.6% · +5d +3.2%
› 2 waves of this story2026-10-02 First-and-only non-covalent BTK inhibitor expands to first-line, broadening patient pool2026-10-05 FDA expands Jaypirca label to first-line setting, bolstering Lilly's oncology portfolio2026-10-02 Product Bull
Lilly Highlights New Efficacy Data from Foundayo and EloraTZP Foundayo shows CV safety; EloraTZP mid-stage delivers greater weight loss and A1C reduction
D1 -0.6% · +5d +3.2%
2026-10-01 Product Bull
Lilly's Oral GLP-1 Foundayo Shows CV Safety in Phase 3 Largest/longest T2D study confirms A1C reduction, weight loss, and CV safety, boosting oral GLP-1 franchise
D1 -0.6% · +5d +1.7%
2026-09-29 Product Bull
Lilly's oral drug shows edge over oral semaglutide in new analysis Indirect comparison shows Foundayo 17.2mg superior in weight loss and A1C reduction vs oral semaglutide 25mg
D1 +0.0% · +5d -2.3%
2026-09-25 → 09-28 Product Bull
FDA Approves Lilly's Olumiant for Severe Alopecia Areata in Adolescents FDA expands Olumiant use to pediatric patients 12+ with severe alopecia areata, following strong phase III results.
D1 +0.1% · +5d -3.4%
› 2 waves of this story2026-09-25 Expands indication to adolescents, based on first pediatric Phase 3 data2026-09-28 FDA expands Olumiant use to pediatric patients 12+ with severe alopecia areata, following strong phase III results.2026-09-28 Company
Lilly Launches Commitment to Expand Diabetes and Obesity Drug Access in LMICs Company announcement aims to expand access to innovative medicines in resource-limited settings by 2040, affecting long-term market reach.
D1 +0.1% · +5d -3.5%
2026-09-27 Product
Lilly Discontinues GLP-1 Weight-Loss Drug, Highlighting High Bar Discontinuation reflects high efficacy bar; GLP-1 still >65% of revenue
D1 +0.1% · +5d -3.5%
› 2 waves of this story2026-09-27 Drug failed efficacy bar; GLP-1 franchise still >65% of revenue.2026-09-27 Discontinuation reflects high efficacy bar; GLP-1 still >65% of revenue2026-09-24 → 09-27 Regulation Bull
FDA Approves Lilly's Once-Weekly Insulin Onswik, Stock Nears $1,200 FDA approval of Onswik is a major product milestone, but stock up 60% raises questions on market impact
D1 +2.7% · +5d -2.7%
› 2 waves of this story2026-09-24 Onswik offers once-weekly basal insulin for adults with T2D, potentially reducing injections by >300 per year2026-09-27 FDA approval of Onswik is a major product milestone, but stock up 60% raises questions on market impact2026-09-26 Company
Jury Awards $90M to Nektar in NKTR v. Lilly Case Award below market expectations, but verdict still impacts Lilly's finances.
D1 +0.1% · +5d -3.5%
› 2 waves of this story2026-09-26 Related to rezpegaldesleukin deal breach; verdict subject to post-trial2026-09-25 Award below market expectations, but verdict still impacts Lilly's finances.2026-09-24 Company
Lilly and InnoCare Enter Multi-Target R&D Collaboration Collaboration covers up to five targets; InnoCare eligible for milestones, deepening innovative drug development
D1 +2.7% · +5d -2.7%
2026-09-22 Regulation Bull
FDA Grants Full Approval to Lilly's Inluriyo Combo for Breast Cancer Inluriyo gets full FDA approval with Verzenio for pretreated ESR1-mutated breast cancer.
D1 +0.5% · +5d +1.2%
2026-09-22 Company Bull
Lilly Breaks Ground on $6.5B Houston Plant for Oral GLP-1 Drug Facility to make APIs for Foundayo, part of Lilly's U.S. manufacturing expansion, creating 600+ jobs.
D1 +0.5% · +5d +1.2%
2026-09-21 Product Bear
Novo's CagriSema Shows Superior Weight Loss vs Lilly's Tirzepatide Competitor clinical data may impact Lilly's weight-loss market share
D1 +1.0% · +5d +1.7%
2026-09-21 Capital
Lilly Signals Up to $100M Interest in Oura IPO Strategic investment in smart ring maker for health monitoring
D1 +1.0% · +5d +1.7%
2026-09-19 Regulation Bull
FDA Approves Lilly's Inluriyo + Verzenio for ESR1-Mutated Breast Cancer Lilly's combo therapy approved for advanced breast cancer with ESR1 mutation
D1 +1.0% · +5d +1.7%
2026-09-17 Product Bull
Eli Lilly GLP-1 H1 Sales Hit $27.7B, Oral Drug Share Grows Mounjaro/Zepbound drive growth; oral pill Foundayo captures >30% new patient share
D1 +1.3% · +5d +2.6%
2026-09-16 Company
Lilly Partners with Twist Bioscience for AI Drug Discovery Collaboration leverages AI to accelerate drug discovery, potentially enhancing Lilly's pipeline efficiency
D1 +0.2% · +5d +1.2%
2026-09-15 Analyst Bull
Berenberg Upgrades Eli Lilly to Buy, Raises PT to $1,400 Analyst cites strong returns, obesity leadership, and pipeline diversification
D1 -0.2% · +5d +3.0%
2026-09-15 Product Bull
Eli Lilly Pipeline Strength Highlighted by Positive Retatrutide and Foundayo Data Previews Positive late-stage obesity and diabetes pipeline previews underscore R&D strength
D1 -0.2% · +5d +3.0%
